BEDMINSTER, N.J. - Matinas BioPharma Holdings, Inc., an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics for the treatment of cardiovascular and metabolic conditions, announced in a press release it received a Notice of Allowance from the US Patent and Trademark Office ("USPTO") for US Patent Application Serial No. 14/101,165 entitled, "Methods of Administering Compositions Comprising Docosapentaenoic Acid." Upon issuance, the patent will provide intellectual property protection through 2033. 

 

The allowed patent claims cover the Company's proprietary methods related to reducing triglyceride levels by administering a pharmaceutical composition comprising omega-3 docosapentaenoic acid (DPA) to patients.  

Roelof Rongen, President and Chief Executive Officer of Matinas BioPharma, commented, "The patent allowance for our proprietary omega-3 DPA composition related to our lead product candidate MAT9001 represents a significant achievement for Matinas BioPharma. The timing of this allowance is ideal as we prepare to commence our Phase 3 registration program of MAT9001 in 2015."

 

Jerome D. Jabbour, Chief Business Officer and General Counsel of Matinas BioPharma, added, "Establishing a robust patent estate is one of the Company's strategic imperatives. The issuance of this patent will further strengthen our protection in the United States for MAT9001 and is a clear example of our ongoing efforts and commitment to solidifying a comprehensive intellectual property portfolio for our development programs."

The USPTO issues a Notice of Allowance after it makes a determination that a claimed invention is novel and nonobvious in light of all known technology in existence, and that a patent should be granted from such an application. Based on the timing of this Notice of Allowance, Matinas BioPharma expects the forthcoming DPA patent to be issued by the end of 2014.